Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)

China flag China · Delayed Price · Currency is CNY
6.21
-0.19 (-2.97%)
At close: Apr 9, 2026
Market Cap4.08B +11.7%
Revenue (ttm)141.77M +8.8%
Net Income-241.61M
EPS-0.37
Shares Out656.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,461,650
Average Volume11,739,885
Open6.34
Previous Close6.40
Day's Range6.18 - 6.47
52-Week Range4.67 - 10.31
Beta0.65
RSI50.89
Earnings DateMar 28, 2026

About SHA:688373

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment... [Read more]

Sector Healthcare
Founded 2007
Employees 177
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688373
Full Company Profile

Financial Performance

In 2025, SHA:688373's revenue was 141.77 million, an increase of 8.83% compared to the previous year's 130.27 million. Losses were -241.61 million, -45.18% less than in 2024.

Financial Statements